Intrahepatic cholangiocarcinoma (ICC) is a rare cancer with a poor prognosis. Surgery is the main curative option but up to…
Josep Tabernero
We are delighted to announce that our Director Josep Tabernero is among the selected candidates for the American Association for…
Presented by VHIO’s Director Josep Tabernero during this week’s annual ASCO Gastrointestinal Cancers Symposium, January 19-21, results from the phase…
Recently published in Nature Reviews Gastroenterology & Hepatology*, a comprehensive Review focused on gastric cancer and gastro-oesophageal junction cancer (GC-GOJC)…
Published today, Clarivate has revealed its annual #HighlyCited2022 researchers list. Featuring among the world’s elite scientists at academic research institutes and…
Co-authored by Ana Vivancos, Principal Investigator of VHIO’s Cancer Genomics Group, and VHIO’s Director Josep Tabernero, a News & Views…
The Coordination and Support Action “4.UNCAN.eu” had its official kick-off on September 8-9 2022 with a public event hosted by…
The multicenter randomized phase III BREAKWATER trial, spearheaded by VHIO, is the first to evaluate the combination of study drugs…
Founded by Cancer Research UK (CRUK) and the National Cancer Institute (NIH-NCI, USA) the Cancer Grand Challenges are internationally funded…
The “J-BID – José Baselga Innovative Disruption Program” has an investment of up to 6 million euros and aims to…
